Vantage publishes its annual look ahead to 2019, examining the trends and issues that will shape biopharma in the coming year.
Two readouts are approaching for Axsome's AXS-05, and Aldeyra is facing a data-heavy 2019.
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
The decision to halt trials for the uterine fibroid product marks another setback in an area where there are few suitable solutions for patients.
The latest Lentiglobin data impress, but launch worries could clip Bluebird’s wings.
December will be a big month for Achillion's complement inhibitor and Aquestive's ALS hopes.
Approval of a cystic fibrosis triplet from Vertex looks odds-on – and with the competition lagging behind, the company has free rein on price.
Showing a cardiovascular benefit would have been icing on the cake for Novo Nordisk’s oral GLP-1 agonist, but the data still look strong enough to support blockbuster…
Masterkey-265 will test the sector’s renewed interest in oncolytic viruses as a way of turning “cold" tumours "hot”.